EndoAid

Company Overview

Snapshot

Founded in March 2013 by Omer Shezifi, EndoAid operates with 1–10 employees. The company has raised $600,000 across one funding round from one investor. In December 2014, US Endoscopy entered into a distribution partnership with EndoAid for the EndoRings device portfolio in the United States.

Business overview

EndoAid develops tools to enhance gastroenterology procedures, focusing on improved visualization and screening. Its core product, the EndoRings Distal Attachment, is a silicone-based endoscopic add-on device designed to fit various endoscopes. This device features a short, tube-like core with flexible circular rings that fold backward during scope advancement to minimize resistance and open the colon. During scope removal and colon screening, the rings center the scope and smooth colon folds, thereby expanding the field of view and improving the accuracy of visualization and screening. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Diagnostics Devices markets, serving healthcare providers.

Strategic signal

In December 2014, EndoAid secured a distribution partnership with US Endoscopy, making US Endoscopy the exclusive distributor for the EndoRings device portfolio in the United States. This agreement is a significant validation of EndoAid's technology and provides a clear pathway for market penetration and adoption within the critical US healthcare market, signaling strong commercial potential to investors.

Company Intelligence Q&A

What is EndoAid's primary product?

EndoAid's primary product is the EndoRings Distal Attachment, an endoscopic add-on device made from silicone. It features a tube-like core with flexible circular rings designed to improve visualization and screening during colonoscopies by smoothing colon folds and enhancing the field of view.

When was EndoAid founded and by whom?

EndoAid was founded in March 2013 by Omer Shezifi, who serves as Co-founder & VP R&D.

What significant partnership did EndoAid secure for its EndoRings device?

In December 2014, EndoAid entered into a distribution partnership with US Endoscopy, which became the exclusive distributor for the EndoRings device portfolio in the United States.

What were the findings of the study on the EndoRings colonoscopy?

In May 2014, a study indicated that patients undergoing an EndoRings colonoscopy followed by a standard colonoscopy showed significantly lower polyp and adenoma miss rates, suggesting the device is safe and effective in improving detection rates compared to standard colonoscopy.

What is the total capital raised by EndoAid?

EndoAid has raised a total of $600,000 across one funding round.